Latest News

aHSCT webinar: World MS Day 2023

May 24, 2023 | Education, Event, Life with MS, Treatments, Webinar

Multiple Sclerosis New Zealand (MSNZ) and the New Zealand Multiple Sclerosis Research Trust (NZMSRT) are pleased to invite you to our webinar to mark World MS Day on 30 May. Autologous haematopoetic stem cell transplant (aHSCT) has captured the interest […]


Update: Siponimod (Mayzent) for Secondary Progressive MS

November 16, 2022 | Advocacy, Funding, Treatments

At the August 2022 meeting of PHARMAC’s Pharmacology and Therapeutics Advisory Committee (PTAC), Multiple Sclerosis NZ (MSNZ) made a submission in support of the funding of Siponimod (Mayzent) for Secondary Progressive MS. At this meeting PTAC recommended listing with low priority and have requested further advice from the […]


Important notice for MS patients regarding Evusheld

November 16, 2022 | Advocacy, Covid-19, Treatments

Important notice for MS patients regarding EvusheldTM. EvusheldTM is a pre-exposure prophylaxis, which has shown positive results for reducing the impacts of COVID-19 on those who may lowered immunity against COVID 19 due to their MS treatments. Evusheld is NOT […]


Making progress to make Autologous Hematopoietic Stem Cell Treatment (aHSCT) an available treatment option in NZ for MS

September 14, 2022 | Advocacy, Treatments

Autologous Hematopoietic Stem Cell Treatment (aHSCT) is an intense chemotherapy treatment which aims to wipe out harmful immune cells and rebuild the immune system. aHSCT is a life-improving treatment halting the disease and disability in its tracks. A person receiving […]


Addressing the unmet need

September 14, 2022 | Advocacy, Progressive, Treatments

Currently, only approximately 1900 of the over 4130 New Zealanders diagnosed with MS are able to access funded Disease Modifying Therapies (DMTs). In particular, those with progressive forms of MS, Secondary (SPMS) and Primary Progressive MS (PPMS), have extremely limited […]